Blood concentration monitoring of hydroxychloroquine in patients with autoimmune diseases

doi:10.12092/j.issn.1009-2501.2018.12.007

Abstract

Abstract:

AIM: To explore the factors that influence the blood concentration of hydroxychloroquine (HCQ) including dosage, treatment course, and combination of the drug (hormone, cyclophosphamide, mycophenolate mofetil and methotrexate), as well as the disease type, age and gender of the patients. METHODS: During July 2017 to June 2018, blood samples were collected from autoimmune diseases patients who had been treated with HCQ for more than 6 months in department of rheumatology and immunology of our hospital. The blood concentration of HCQ was monitored by high performance liquid chromatography (HPLC). Statistical analyses were performed by SPSS 16.0. RESULTS: The blood concentration of HCQ was relatively high in patients treated with 0.4 g HCQ per day. Patients that over 50 years old and/or have been treated with HCQ for more than 10 years presented significant higher HCQ blood concentration (P<0.05). Other factors including disease type, gender and drug combination didn't obviously affect the concentration of HCQ. Moreover, we found that the incidence of adverse drug reactions was increased along with the increase of HCQ blood concentration. CONCLUSION: The blood concentration of HCQ is mainly affected by the dosage, the age of the patients, and the course of HCQ treatment. The equivalent therapeutic effect can be achieved with lower HCQ dosage in elderly and long-term treatment patients. Adjustment the dosage according to the blood HCQ concentration monitoring could decrease the incidence of adverse drug reactions.

Key words: hydroxychloroquine, blood concentration, autoimmune diseases, influence factors analysis

CLC Number:

LIU Tingting, YU Wei, YANG Chunlan, SHUAI Zongwen, GAO Beibei, XIA Quan. Blood concentration monitoring of hydroxychloroquine in patients with autoimmune diseases[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1359-1363.

References

［1］李小心，徐亮. 类风湿性关节炎缓解后的维持治疗研究进展［J］. 中国临床药理学与治疗学，2014,19(1): 116-120.
［2］Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: An old drug with new relevance［J］. Cleve Clin J Med,2018,85(6):459-467.
［3］国家风湿病数据中心及CSTAR专家共识组. 羟氯喹治疗风湿性疾病专家共识［J］. 中华风湿病学杂志，2014,18(3) :148-150.
［4］Monzavi SM, Alirezaei A, Shariati-Sarabi Z, et al. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers［J］. Inflammopharmacol,2018 Jul 10. ［Epub ahead of print］
［5］罗雪梅，司慧敏，姚瑶，等. 全血及血清中羟氯喹HPLC测定方法的建立及其应用［J］. 药学与临床研究，2015,(6): 562-564.
［6］Qu Y, Noe G, Breaud AR, et al. Development and validation of a clinical HPLC method for the quantification of hydroxychloroquine and its metabolites in whole blood［J］. Future Sci OA, 2015,1(3): FSO26.
［7］Espinosa E,Valitutti S,Laroche M,et al.Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases［J］.Clin Immunol,2018,194:75-79.
［8］Tanaka E,Taniguchi A,Urano W,et al.Pharmacogenetics of disease-modifying anti-rheumatic drugs［J］.Best Pract Res Clin Rheumatol,2004,18(2):233-247.
［9］Ma H, Zhao L, Jiang Z, et al. Dynamic changes in the numbers of different subsets of peripheral blood NK cells in patients with systemic lupus erythematosus following classic therapy ［J］. Clin Rheumatol,2014,33(11): 1603-1610.
［10］解方，赵梓纲，赵华. 吡美莫司乳膏联合羟氯喹片治疗扁平苔癣的疗效及安全性观察［J］. 中国药物应用与监测，2012,9(2): 70-72.
［11］Tétu P, Hamelin A, Lebrun-Vignes B, et al. Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: A retrospective survey of 102 patients ［J］. Ann Dermatol Venereol, 2018,145(6/7): 395-404.
［12］Moya FB,Pineda Calindo LF,Carcia de la Pena M.Impact of chronic glucocorticoid treatment on cardiovascular risk profile in patients with systemic lupus erythematosus［J］.J Clin Rheumatol,2016,22(1): 8-12.
［13］沈斌，张斌，徐亮，等. 风湿免疫科门诊超说明书用药调查与分析［J］. 中国临床药理学与治疗学，2017,22(3): 337-341.
［14］Bruni C, Praino E, Guiducci S, et al. Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center［J］. Joint Bone Spine,2017,84(6): 747-748.
［15］徐冬，吕晓伟，崔鹏，等. 艾拉莫德与羟氯喹治疗干燥综合征患者疗效及安全性比较［J］. 疑难病杂志，2017,16(9): 915-918.
［16］Lee JY, Vinayagamoorthy N, Han K, et al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus［J］. Arthritis Rheumatol,2016,68(1): 184-190.
［17］韩龙，孙桂芳. 滋阴润燥生津汤联合硫酸羟化氯喹治疗干燥综合征临床研究［J］. 中医药信息，2014,(3): 60-63.
［18］中华医学会风湿免疫分会.类风湿关节炎诊断及治疗指南［J］.中华内科杂志，2018,57(4):242-251.
［19］中华医学会风湿免疫分会. 系统性红斑狼疮诊断及治疗指南［J］. 中华风湿病学杂志，2010,14(4): 265-270.
［20］Jallouli M, Saadoun D, Eymard B, et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature［J］. J Neurol,2012,259(7):1290-1297.

[1]	DU Wenpeng, AO Jiangen, TAO Yi, WU Guansheng, HE Jiake. Study on the factors affecting the steady-state blood concentration of tacrolimus in patients with autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 645-651.
[2]	LU Ming, YIN Xiaoyu, ZHANG Zhiqing. Research progress and mechanism of mesenchymal stem cells in the treatment of autoimmune diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 700-706.
[3]	SUN Qing, SUN Jianfang, LI Li, CHANG Huichao, ZHOU Quan. Effects of Wuzhi capsule on the pharmacokinetics of simvastatin and its metabolite simvastatin acid in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1242-1249.
[4]	LI Qing, XIN Hua-wen, WU Xiao-chun, YU Ai-rong, XIONG Lei. Clinical study for the effects of Wuzhi-capsule on blood concentration of tacrolimus in renal transplant recipients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(7): 804-807.
[5]	PANG Xiao-yun, SHEN Jin-fang. Influence of planta medica on the blood concentration of tacrolimus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 110-112.
[6]	ZHANG Qing, CHEN Hong, ZHANG Li, TIAN Yan, NIU Yu-jian, LI Qin, CHEN Xin-guo, ZANG Yun-jin, SHEN Zhong-yang. Evaluation of tacrolimus combining with liver-aid tablet in the treatment of acute rejection after liver transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(11): 1286-1290.
[7]	WU Jing, WANG Ben-jie, WEI Chun-min, KONG Xiang-lin, GUO Rui-chen. Determination of paeonol in human plasma by HPLC and its pharmacokinetic studies [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 935-938.
[8]	ZHENG Zhuan-jie, FANG Yi, WANG Rui. Measurement of recombinant human glucagon-like peptide-1 (7-36) concentration by ELISA kit methods [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(4): 444-447.
[9]	SUN Cheng-Chun, ZHAO Xiao-Yuan, CAO Yang, WANG Jing-Xiang. Effect of clarithromycin on pharmacokinetics of aminophylline at steady state in rabbits [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(1): 21-23.
[10]	SUN Cheng-Chun, ZHANG Li, WANG JingXiang. Effect of ketoconazole on concentration and Pharmacokinetics of aminophyllin in blood [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1998, 3(1): 38-40.
[11]	Wang Feng, Zhang Huafeng, Li Ying, Su Shiping, Sun Bin. Determination of cyclosporine A by the fluorescence polar-ization immunoassay methods in renal transplant recipients and the influence of hepatic function on CsA concentration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1996, 1(1): 13-16.